摘要
目的探讨乳腺癌组织中不同骨桥蛋白(OPN)的表达水平及其与微血管密度的关系。方法采用免疫组织化学Envision法检测89例乳腺浸润性导管癌组织OPN和CD34的表达情况,分析其表达与病理特征的关系。定性资料分析采用χ2检验,定量资料分析采用t检验。结果在89例乳腺浸润性导管癌中,OPN阳性表达率为57.30%(51/89)。组织学分级Ⅰ、Ⅱ、Ⅲ级浸润性导管癌OPN阳性表达率分别为27.27%(6/22)、66.67%(24/36)、67.74%(21/31),三者间差异有统计学意义(χ2=10.780,P=0.005);有、无淋巴结转移者OPN阳性表达率分别为74.47%(35/47)和38.10%(16/42),伴有淋巴结转移者OPN阳性表达率明显高于不伴转移者(χ2=11.993,P=0.001)。乳腺癌组织OPN表达阴性、阳性组的肿瘤微血管密度(MVD)分别为(68.42±23.45)条/每高倍视野和(94.96±31.03)条/每高倍视野,二者间差异有统计学意义(t=4.413,P=0.000)。结论 OPN在乳腺癌组织中的高表达与肿瘤血管的生成和肿瘤的浸润及转移有一定关系,针对OPN的进一步研究可能为临床治疗乳腺癌转移提供新的方法。
Objective To explore the expression of osteopontin in breast carcinoma and its relationship with microvascular density. Methods Envision immunohistochemical method was used to examine the expressions of osteopontin and CD34 in 89 invasive breast carcinoma cases and analyze their relationship with clinical pathological characteristics. Qualitative data were analyzed using chi-square test. Quantitative data were analyzed using t test. Results In the 89 cases of breast invasive ductal carcinoma, the positive rate of osteopontin was 57.30% (51/89). In grade I, II and III invasive ductal carcinoma patients, the positive rate of osteopontin was 27.27% (6/22), 66.67% (24/36) and 67.74% ( 21/31 ), respectively, with statistically significant difference between the three groups of patients ( X~ = 10. 780, P = 0. 005 ). In patients with lymph nodes metastases and without lymph nodes metastases, the positive rate of osteopontin was 74.47% (35/47) and 38.10% ( 16/42 ) respectively, showing a high positive rate of osteopontin patients with lymph nodes metastases than without ( X2 = 11. 993,P= 0. 001 ). The microvessel density was (68.42 ±23.45 ) per high- power field in patients with negative expression of osteopontin and (94.96 ± 31.03 ) per high-power field in patients with positive expression of osteopontin, with statistically significant difference between the two groups (t =4. 413, P=0.000). Conclusion High expression of osteopontin in breast cancer may have some relationship with tumor angiogenesis and tumor invasion and metastasis. Further study on the role of osteopontin in breast cancer blood vessels will provide a new method for the clinical treatment of breast cancer metastasis.
出处
《中华乳腺病杂志(电子版)》
CAS
2011年第4期20-23,共4页
Chinese Journal of Breast Disease(Electronic Edition)